PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
March 22, 2024Cancer Research

Abstract 3148: ABBV-706 is a novel SEZ6-targeted topoisomerase 1 inhibitor ADC for SCLC and other neuroendocrine cancers

View Full Paper
Ask AI
Bookmark
Share

Authors

EFEmily J. FaivreMPMarybeth A. PyszEHEoghainín Ó hAinmhire

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Faivre et al. (2024) studied this question.

synapsesocial.com/papers/68e72cdcb6db6435876a6850https://doi.org/10.1158/1538-7445.am2024-3148
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1SEZ6-Targeted ADC Shows Preliminary Efficacy in Small Cell Lung Cancer2026
  2. 2SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial2026 · 3 citations
  3. 3Abstract 7815: Efficacy of ABBV-706, a SEZ6-targeted topoisomerase 1 inhibitor ADC: A report from the Pediatric Preclinical In Vivo Testing (PIVOT) Program2026
  4. 4First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.2024 · 31 citations
  5. 5Author Correction: SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial2026